Abstract
Purpose: Previous meta-analyses of randomised controlled trials (RCTs) of bisphosphonates in osteoarthritis (OA) have been negative, but heterogeneity is high and results remain controversial. People with high bone turnover have the greatest capacity to benefit from bisphosphonate therapy. Therefore, the aim of this study was to summarise effects of intravenous bisphosphonates (IVBP) on knee pain, function, bone marrow lesion (BML) size, and safety outcomes in RCTs of patients with symptomatic knee OA and a marker of high bone turnover (BMLs), compared to placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
